Latest news from The Englander Institute for Precision Medicine:
Researchers can now predict the odds of experimental drugs succeeding in clinical trials, thanks to a new data-driven approach developed by Weill Cornell Medicine scientists. The method detects toxic side effects that may disqualify drugs from human use, giving drug developers an early warning before initiating clinical trials, according to a new study published Sept. 15 inCell Chemical Biology.
In order to benefit from the latest advances in precision medicine, Himisha Beltran, M.D., has to subject her prostate cancer patients to invasive biopsies that can be painful, expensive, difficult to perform, and not always feasible.
But she is hoping to harness new genomic sequencing technologies to track tumor activity from a simple blood draw, and a $1 million grant from the Prostate Cancer Foundation may help make the dream a clinical reality.